The Effect of Sedation on Eye Movements

This study has been completed.
Information provided by (Responsible Party):
Michael Froelich, University of Alabama at Birmingham Identifier:
First received: March 25, 2008
Last updated: April 8, 2014
Last verified: April 2014
Results First Received: June 27, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacokinetics/Dynamics Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Basic Science
Condition: Saccadic Eye Movements
Interventions: Drug: propofol
Drug: dexmedetomidine
Drug: Midazolam
Drug: saline placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment was held at the Clinical Research Unit in Jefferson Towers. There were 65 participants recruited between March 28, 2008 and September 24, 2008. All participants signed a written informed consent and was verified to all the information pertaining to their participation in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A physical examination of each participant was used to assess their success in the study. Participants were excluded if they did not meat the BMI weight requirement and/or wanted to be excluded from the study.

Reporting Groups
Dexmedetomidine Sedative Drug 1
Midazolam Sedative Drug 2
Placebo Placebo Control
Propofol Sedative Drug 3

Participant Flow:   Overall Study
    Dexmedetomidine     Midazolam     Placebo     Propofol  
STARTED     15     15     15     20  
COMPLETED     15     15     15     20  
NOT COMPLETED     0     0     0     0  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups


dexmedetomidine : Sedative



Midazolam : sedative


placebo control

saline placebo : saline placebo


active drug

propofol : sedative

Total Total of all reporting groups

Baseline Measures
    Dexmedetomidine     Midazolam     Placebo     Propofol     Total  
Number of Participants  
[units: participants]
  15     15     15     20     65  
[units: participants]
<=18 years     0     0     0     0     0  
Between 18 and 65 years     15     15     15     20     65  
>=65 years     0     0     0     0     0  
[units: years]
Mean (Standard Deviation)
  30.8  (9.22109)     32  (6.94879)     34.93333  (11.09998)     34.93333  (12.49838)     33.16666  (2.09797)  
[units: participants]
Female     9     7     10     9     35  
Male     6     8     5     11     30  
Region of Enrollment  
[units: participants]
United States     15     15     15     20     65  

  Outcome Measures

1.  Primary:   Dynamic Eye Movement Measures   [ Time Frame: baseline to Sedation State (approx. 1 hr) ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Michael Froelich
Organization: University of Alabama at Birmingham
phone: 205-934-4711

No publications provided

Responsible Party: Michael Froelich, University of Alabama at Birmingham Identifier: NCT00646646     History of Changes
Other Study ID Numbers: F050721005, K23 RR021874-01 A1
Study First Received: March 25, 2008
Results First Received: June 27, 2013
Last Updated: April 8, 2014
Health Authority: United States: Food and Drug Administration